Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3910
Shown on this page
12
Current sort
Recently updated
Condition scope
Prostate Cancer
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings
castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Prostate Cancer. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 121–132 of 3,910 matching trials for Prostate Cancer.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional Results available

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197
View directory record Official record
Conditions
mCRPC
Interventions
Talazoparib with enzalutamide, Placebo with enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
132
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Duarte, California • Encino, California • South Pasadena, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622
View directory record Official record
Conditions
Prostate Cancer
Interventions
talazoparib plus enzalutamide, Placebo plus enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Suspended Phase 2 Interventional

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05445609
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
VLP-encapsulated TLR9 Agonist CMP-001,, Nivolumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting No phase listed Observational

Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)

NCT06960798
View directory record Official record
Conditions
Prostate Cancer, Renal Cell Carcinoma (RCC)
Interventions
Bio-specimen Collection, Blood Draw
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT06511141
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions
Axonics SNM System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Early Phase 1 Interventional

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

NCT05045066
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Locally Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Interventions
Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection
Dietary Supplement · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen

NCT07141121
View directory record Official record
Conditions
Prostate Cancer
Interventions
Histolog Scan
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

EMBRACE: Exercising Together

NCT06049355
View directory record Official record
Conditions
Breast Carcinoma, Prostate Carcinoma
Interventions
Exercise Intervention, Biospecimen Collection, Educational Intervention
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Active, not recruiting Not applicable Interventional

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

NCT04905069
View directory record Official record
Conditions
Prostate Cancer
Interventions
SpaceOAR Vue System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
7
States / cities
Fort Myers, Florida • Tampa, Florida • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
46
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:40 AM EDT

About this Prostate Cancer clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Prostate Cancer.